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The mechanisms underlying sperm protein 17 (Sp17) gene expression in myeloma cells remained unclear. Using reverse
transcription–polymerase chain reaction (RT–PCR), Sp17 transcripts were detected in ARK-B, ARP-1, RPMI-8226 and KMS-11 but
not in H929, IM-9, MM1-R and U266 cells. Using a panel of primer pairs in methylation-sensitive PCR to amplify overlapping gene
segments, our screening studies showed that the HpaII sites at  359 and  350 are involved in the regulation of Sp17 gene
expression. To confirm the differences in methylation status between Sp17-positive and Sp17-negative cell lines, KMS-11 cells (Sp17-
positive) and IM-9 cells (Sp17-negative) were subjected to the more accurate method of bisulphite conversion. KMS-11 cells were
more hypomethylated at these HpaII sites of exon 1 compared to IM-9 cells, indicating the association of hypomethylated promoter
with Sp17 gene expression. In addition, the level of methylation at other CpG sites within the promoter sequence was also higher in
IM-9 than KMS-11. Exon 1 was cloned into a reporter vector, pCAT*3 Enhancer. Chloramphenicol acetyl transferase (CAT) activity
was restored in cells transfected with the recombinant plasmid, indicating the promoter function of exon 1. Exposure of Sp17-
negative cell lines to the hypomethylating agent, 5-azacytidine, resulted in the upregulation of Sp17 gene expression. Our results
therefore provide evidence for the regulation of Sp17 gene expression by promoter methylation.
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Sperm protein 17 (Sp17) is a 22–24kDa normal testicular protein
aberrantly expressed by tumour cells from patients with multiple
myeloma (MM) (Lim et al, 2001) and ovarian cancer (Chiriva-
Internati et al, 2002a). It has also been found to be expressed by
tumour cells from some malignant melanoma, astrocytoma and
colon cancer (unpublished). It is a cancer-testis (CT) antigen
expressed only in normal testis and some tumour cells but not in
any other normal tissues (Lim et al, 2001; De Jong et al, 2002).
Sperm protein 17-specific CD8þ cytotoxic T-lymphocytes (CTLs)
reactive with Sp17-positive HLA-matched fresh tumour cells could
be generated from the peripheral blood of healthy donors (Chiriva-
Internati et al, 2001, 2002b) and cancer-bearing patients (Chiriva-
Internati et al, 2002a,c). The restricted normal tissue expression of
Sp17 and the ability to generate tumour-reactive specific CTLs
suggest that Sp17 may be a potential target for tumour vaccines of
Sp17-positive tumours.
Sp17 is involved in the interaction of spermatozoa with oocytes
after acrosome reaction (in mouse) (Kong et al, 1995) and after
sperm–zona pellucida contact is initiated (in rabbit) (Richardson
et al, 1994). In addition, it has a functional role in cell regulation
by participating in signalling pathways through its calmodulin
binding site at the C-terminal (Wen et al, 2001). The N-terminal is
similar to a cAMP-dependent protein kinase regulatory subunit
and the central domain participates in heparin binding (Lacy and
Sanderson, 2001; Wen et al, 2001). The gene encoding Sp17 is
mapped by sequence database to chromosome 11 in human. It
contains five exons and four introns (Buchli et al, 2002). There are
two transcriptional start sites, designated Sp17-1a and Sp17-1b.
Recently, an intronless Sp17 pseudogene (Sp17-2) has been
identified in human in chromosome 10 and is attributed to RNA
retroposition.
COS cells transfected with Sp17 cDNA showed Sp17 in their
cytoplasm (Yamasaki et al, 1995). Although Sp17 does not have a
transmembrane domain, Sp17 was also found on the surface of live
COS cells. The explanation for this observation is not apparent. It
is possible that Sp17 has an unknown mechanism for arriving at
the cell surface by lipid associations or carrier proteins.
Alternatively, it could have arisen due to cell death and subsequent
release of cytoplasmic Sp17 that became associated with the
membrane.
Even though Sp17 shows a restricted normal tissue expression,
the mechanisms regulating Sp17 aberrant expression in myeloma
cells are not known. We therefore set out to determine the
mechanisms of the Sp17 gene expression since such information
may provide the opportunity to manipulate the gene for
therapeutic purposes. Changes in gene methylation occur fre-
quently in cells that have undergone malignant transformation.
These changes are thought to be responsible for the aberrant
expression of the genes encoding some CT antigens. Since Sp17 is a
CT antigen, we hypothesised that Sp17 gene expression might be
controlled by methylation of the promoter sequence so that the
gene is silenced by DNA methylation. To test this hypothesis, we
have investigated Sp17 gene expression in eight MM cell lines and
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status of the tumour cell lines.
MATERIALS AND METHODS
MM cell lines
Eight MM cell lines were used: ARK-B and ARP-1 (gifts from
Joshua Epstein, PhD, University of Arkansas for Medical Sciences,
Little Rock, AR), H929, KMS-11 and RPMI 8226 (gifts from
Raymond Comenzo, MD, Memorial Sloan Kettering Cancer Center,
New York, NY), IM-9 and U266 (gifts from Dharminder Chanhan,
PhD, Dana Farber Cancer Center, Boston, MA) and MM1-R (gift
from Steve Rosen, MD, Northwestern University, Chicago, IL). All
cell lines were maintained at liquid culture prior to being used for
the experiments.
Reverse transcription–polymerase chain reaction
(RT–PCR) amplification of Sp17 mRNA
Reverse transcription–polymerase chain reaction performed.
Briefly, all RNA specimens were first treated with DNAse I
(Ambion Inc., Austin, TX, USA) to remove genomic DNA
contamination. First-strand cDNA was synthesised from 1mgo f
total RNA using a random hexamer primer. The PCR primers were
50SP17PCR: 50-CAG CAG AAT GGG GGA GTA AG-30; and
30SP17PCR: 50-CAG CTT GGA TTT TGA CAG CA-30. Polymerase
chain reaction was performed using 35 amplification cycles at an
annealing temperature of 601C. Negative controls in all the PCR
reactions contained the PCR reaction mixture except for cDNA,
which was substituted with water. RNA integrity in each sample
was checked by amplification of a b-actin gene segment. Successful
removal of genomic DNA contamination was confirmed in each
sample by amplification of the RNA without prior RT reaction.
Polymerase chain reaction products were visualised on an
ethidium bromide agarose gel. All results were confirmed on two
independent RT–PCRs.
Methylation-sensitive PCR
A panel of oligonucleotide primers was used to amplify over-
lapping gene segments on the Sp17 exon 1 or a control gene
segment in exon 5 of Sp17 gene (Table 1). Genomic DNA was
extracted from tumour cells using a commercially available DNA
extraction kit. The DNA was digested for 3h at 371C with 10Umg
 1
methylation-sensitive restriction enzyme HpaII, extracted with
phenol and chloroform–isoamyl alcohol (25:24:1), and recovered
by ethanol precipitation. To ensure completion of digestion, the
above process was repeated. This restriction digest protocol has
been used successfully in previous works (De Smet et al, 1996;
Sigalotti et al, 2002) and has been found to result consistently in
complete digestion of the genomic DNA by HpaII restriction
enzyme. Following ethanol precipitation, 100ng of the digested
DNA was used for amplification in a final volume of 50ml PCR
mixture. Polymerase chain reaction was carried out for 30 cycles in
a thermal cycler. Polymerase chain reaction products were
analysed on a 2% agarose gel and visualised by ethidium bromide
staining. All results were confirmed in two independent PCR.
Sodium bisulphite genomic DNA modification
Genomic DNA was first digested with EcoRI, then denatured with
0.3 M NaOH for 15min. The denatured DNA was then reacted with
3.6 M sodium bisulphite and 1mM hydroquinone (551C for 14h).
The DNA was desalted using a DNA clean-up kit (Wizard DNA
Clean Up, Promega, Madison, WI) and precipitated for PCR.
Polymerase chain reaction was carried out using the oligonucleo-
tide primers that amplify the whole exon 1 of Sp17 gene: 50-ACC
TAA CTA GCT TCG CCT CCT TC-30; and 50-CTC CTT TCT CTC
CGA GCT GGT GC-30. The PCR products were cloned into the TA-
cloning system. Eight recombinant clones were randomly picked
from each transfection for nucleotide sequence analysis to
determine the proportion of hypomethylated promoter sequence.
In vitro methylation of plasmids, cell transfection and
analysis of chloramphenicol acetyl transferase (CAT)
expression
Sp17 promoter sequence contained within exon 1 was isolated,
amplified and cloned into TA-cloning system for sequence
analysis. The sequence was identical to that published recently
(Buchli et al, 2002). We then subcloned the promoter DNA into the
pCAT*3 Enhancer vector between KpnI and BglII.
The plasmid was methylated in each CpG dinucleotide with SssI
methylase according to the manufacturer’s instruction. Control
Table 1 Oligonucleotide primers used for methylation-sensitive PCR analysis
Primer Primer sequences Gene segment amplified HpaII sites Annealing temperature (1C)
I5 0-CAC CCT TTT GCA GTC CTC GCA GC-30 From position  186 to  28 60
50-CTC CTT TCT CTC CGA GCT GGT GC-30 (IA and IB)
II 50-CGC GAC CAT GCT TGC AAG GA-30 From position –280 to –62 52
50-TTG TTT TTC TAG TTG CTG GG-30 (II)
III 50-GCC GCC TCA CCT GCA CTT CTG TC-30 From position –348 to –227 60
50-GAA CCC ACT TTC CCA GTC CTA GG-30 (III)
IV 50-GCC TCG GTC GGA GAC GCG AGC CC-30 From position –488 to –285 60
50-GGC TTG TAC TCG GGC TGG TGC TG-30 (IVA and IVB)
V5 0-GGT TCA ACC CAG CAG ACT CCT GC-30 From position –518 to –362 60
50-ACC CCT GCC CCT CAG CCT GTG CG-30 (V)
VI 50-ACC TAA CTA GCT TCG CCT CCT TC-30 From position –693 to –493 60
50-TCT GCA GGA GTC TGC TGG GTT GA-30 (VI)
Control 50-GGG ACA CAT AGC CAg AGA G-30 Exon 5, position 377 to 559 52
50-TTC ACA ACA GTA ACG AAT G-30
PCR¼polymerase chain reaction.
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sunmethylated plasmid was obtained under similar experimental
conditions but without the addition of the SssI methylase.
Methylated (pCAT*3 Enhancer-Sp17promoter/met) or unmethy-
lated (pCAT*3 Enhancer-Sp17 promoter) plasmids were purified
by phenol and chloroform extractions, followed by ethanol
precipitation. Successful methylation of the plasmid was confirmed
by restriction digest using methylation-sensitive HpaII. Once
generated, both pCAT*3 Enhancer-Sp17promoter/met and
pCAT*3 Enhancer-Sp17promoter were used to transfect the
human embryonic kidney cell line, 293 cells.
Transfection was carried out using the FuGENE 6 reagent
(Roche Molecular Biochemicals) according to the manufacturer’s
recommendation. Briefly, the cells were seeded into a six-well
cluster plate and grown to 50% confluence. The cultures were
transfected with 2mg of the plasmids and assayed for CAT
activities after 72h. FAST CAT Green (deoxyl) Chloramphenicol
Acetyltransferase Assay Kit (Molecular Probes, Eugene, OR, USA)
was used to detect CAT activity. The transfectants were lysed and a
cytoplasmic extract prepared. The extract was then incubated with
the fluorescent deoxylchloramphenicol substrate and acetyl CoA at
371C. The reaction was terminated by the addition of ice-cold ethyl
acetate. After drying and dissolution in ethyl acetate, the reaction
substrate and product were resolved by thin-layer chromatography
on silica gel plates and eluted with a chloroform:methanol mixture
(85:15 (vv
 1)).
In vitro treatment of myeloma cell lines with 5-azacytidine
Tumour cells were treated with 2mM 5-azacytidine. The
medium was replaced daily with fresh culture medium and
after 96h, the cells were used for molecular analyses. Control
cultures were grown under identical conditions but without
5-azacytidine.
Northern blot analysis
Total RNA was prepared from the cells using a commercially
available RNA preparation kit, RNAEasy (Qiagen, USA). Total
RNA (10mg) from each cell preparation were electrophoresed on a
1.2% agarose/formaldehyde gel and transferred onto a nylon
membrane (MSI, Westboro, MA, USA). Membranes were prehy-
bridised in a commercial NorthernMaxt Prehyb/Hyb buffer
(Ambion, Austin, TX, USA) for 1 to 3h and then hybridised for
18h at 421C. Sperm protein 17 full-length cDNA (approximately
500 base pairs (bp)) and a control cDNA, b-actin fragment
(615bp), templates were labelled by random priming with
[
32P]dCTP using the Ready-to-Go DNA labelling kit
(Amersham Pharmacia Biotech Inc., Pharmacia, Piscataway, NJ,
USA). Final washes of the membranes were performed at 681C
with 1 SSC with 0.25% sodium dodecyl sulfate (SDS)
solution. Binding to Sp17 or b-actin mRNA was visualised by
autoradiograph.
Statistical analysis
Fisher’s exact tests were used to determine the significance of
differences between two variables. A P-value of p0.05 was
considered statistically significant.
RESULTS
Differential Sp17 gene expression in MM cell lines
Using a pair of sequence-specific primers in PCR, we first
determined the expression of Sp17 gene in eight MM cell lines.
Sperm protein 17 mRNA was only detected in ARK-B, ARP-1,
KMS-11 and RPMI 8226 and not the other four MM cell lines
(Figure 1). Although the PCR was not designed primarily to
provide an accurate mRNA quantitation, the reproducibly more
intense signal from KMS-11 suggests a higher level of Sp17 gene
expression in KMS-11 when compared to ARP-1, ARK-B and
RPMI 8226.
Association between Sp17 gene expression and
hypomethylation of specific HpaII sites by methylation-
sensitive PCR
To determine if the heterogeneity of Sp17 gene expression among
the MM cell lines was related to differences in the methylation
status of their promoters, we first used HpaII restriction digest/
PCR analysis to screen the Sp17 promoters in these cell lines. A
total of eight HpaII sites were identified. A panel of primers was
used to amplify overlapping gene segments of the promoter
sequence. The PCR products from primer pair I contain two,
primer pair III one, primer pair V one and primer pair VI one
HpaII sites. No differences in the results from restriction digest/
PCR were observed among the eight MM cell lines, whether Sp17-
positive or Sp17-negative, suggesting that the methylation status at
these HpaII sites may not be directly involved in the regulation of
Sp17 gene expression (Figure 2). The PCR products from primer
pair II contain one HpaII site. Using primer pair II, amplification
products were only obtained from IM-9 and U266 cells. This
indicates that this site is methylated in both cell lines and would be
consistent with failure to express Sp17. However, using the same
primer pair, no amplification products were obtained from the
other two Sp17-negative cell lines, H929 and MM1-R, indicating
that these HpaII sites were hypomethylated in both cases. These
findings therefore suggest that hypomethylation of the HpaII site
within primer pair II is not in itself sufficient to cause Sp17 gene
expression. The PCR products from primer pair IV contain two
HpaII sites (positions  350 and  359). Using HpaII restriction
digest/PCR analysis, amplification products were obtained from all
four Sp17-negative cell lines, H929, IM-9, MM1-R and U266,
suggesting the methylation of either or both of the HpaII sites
within this gene segment of the promoter. In contrast, no PCR
product was obtained from any of the four Sp17-positive tumour
M 1 23456 78
ab cabcabc abcabcabcabc abc
-actin
Sp17
Figure 1 Reverse transcription–polymerase chain reaction analysis using a pair of sequence-specific primers for Sp17 produced a positive signal of
approximately 500bp (lane 1¼ARK-B; lane 2¼ARP-1; lane 3¼H929; lane 4¼IM-9; lane 5¼KMS-11; lane 6¼MM1-R; lane 7¼U266; and lane 8¼RPMI
8226) (M¼molecular marker; lane a¼PCR without prior RT; lane b¼RT–PCR for Sp17; lane c¼control amplification for a b-actin gene segment).
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restriction digest/PCR and Sp17 status of the cell lines suggests
that methylation at one or both of these HpaII sites may be
involved in the regulation of Sp17 gene expression.
Confirmation of association between Sp17 gene expression
and hypomethylation by bisulphite sequencing
Restriction digest/PCR analysis is sensitive to undigested DNA that
will cause amplification of the unmethylated alleles. Therefore, to
confirm the results obtained from restriction digest/PCR indicat-
ing differences in the methylation status of these HpaII sites
between Sp17-positive and Sp17-negative myeloma cells, genomic
DNA from one Sp17-positive, KMS-11, and one Sp17-negative, IM-
9, cells were selected for further analysis by bisulphite conversion.
Following this, the genomic DNA underwent PCR and cloning.
Eight randomly picked recombinant clones were subjected to
nucleotide sequence analysis. We first examined the sequences at
the eight HpaII sites covered by the six primer pairs to validate the
PCR primers we have used. A combination of methylated and
demethylated sequences was obtained, indicating that the primers
we have used were able to amplify both methylated and
demethylated exon 1. Therefore, any results obtained were unlikely
to be due to preferentially amplification of methylated sequences.
We next examine the sequences to validate the results we have
obtained in KMS-11 and IM-9 from restriction digest/PCR. A
complete correlation was observed between the results from
sequence analysis and those from restriction digest/PCR (Table 2).
Only HpaII sites within the gene segments from KMS-11 cells
amplified by primer pairs II and IV showed complete demethyla-
tion, validating the results of the restriction digest/PCR that
showed no PCR product after HpaII digest. In contrast, the other
HpaII sites from KMS-11 or IM-9 all showed variable or complete
methylation, as predicted by the restriction digest/PCR experi-
ments. These results therefore support the notion that methylation
at the two HpaII sites covered by primer pair IV may be involved
in the regulation of Sp17 gene expression. A total of 46 CpG sites
were identified within the Sp17 exon 1. In addition to differences at
the HpaII sites, the 46 CpG sites were more hypomethylated in
Sp17-positive KMS-11 cells (82%, range 80–98%) than Sp17-
negative IM-9 cells (27%, range 4–50%) (Po0.001), indicating the
association of Sp17 gene expression with global promoter
hypomethylation (Figure 3).
Suppression of CAT reporter gene transcription by in vitro
methylation of Sp17 promoter
Exon 1 of Sp17 gene is about 666bp and is rich in CpG
dinucleotides. It fits the criteria for being a CpG island that is
often associated with a promoter region. To prove that exon 1
contains the Sp17 promoter sequence, we used the constructed
pCAT*3 Enhancer-Sp17promoter in a transient transfection study
on 293 human embryonic kidney cells. In contrast to cells
transfected with the wild-type plasmid, CAT activity was obtained
from lysate of cells transfected with pCAT*3 Enhancer-Sp17pro-
moter, confirming that exon 1 contains Sp17 promoter sequence
(Figure 4).
To prove that methylation of the Sp17 promoter was sufficient to
prevent expression, we constructed the reporter plasmids pCAT*3
Enhancer-Sp17promoter/met containing the Sp17 promoters
MM 12 4 6 357 8 9 1 246 357 8 9
AB
Primer pair
I
II
III
IV
V
VI
Control
Figure 2 Polymerase chain reaction analysis for Sp17 promoter sequence using six primer pairs to amplify across eight HpaII sites. Therefore, PCR
products were only obtained if the target sequence are methylated at the HpaII sites (A¼PCR without prior HpaII digest; B¼PCR after HpaII digest) (lane
1¼ARK-B; lane 2¼ARP-1; lane 3¼H929; lane 4¼IM-9; lane 5¼KMS-11; lane 6¼MM1-R; lane 7¼U266; and lane 8¼RPMI 8226) (M¼molecular
marker).
Table 2 % of methylated clones of Sp17+ and Sp17  myeloma cell lines
Location within promoter KMS-11 (Sp17+) IM-9 (Sp17 ) P-values
HpaII site IA 3/8 (37.5%) 6/8 (75%) N.S.
HpaII site IB 4/8 (50%) 6/8 (75%) N.S.
HpaII site II 0/8 (0%) 8/8 (100%) Po0.001
HpaII site III 3/8 (37.5%) 5/8 (62.5%) N.S.
HpaII site IVA 0/8 (0%) 8/8 (100%) Po0.001
HpaII site IVB 0/8 (0%) 7/8 (87.5%) Po0.001
HpaII site V 3/8 (37.5%) 5/8 (62.5%) N.S.
HpaII site VI 2/8 (25%) 6/8 (75%) N.S.
Exon 1 82% 27% Po0.001
Sp17 promoter methylation
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supstream to the CAT report gene. Transient transfection of the
plasmids into 293 human embryonic kidney cells with the
unmethylated construct resulted in CAT gene expression; in
contrast, no CAT activity was observed in transfectants containing
the methylated plasmid (Figure 4). These results therefore confirm
the role of Sp17 promoter methylation in the regulation of Sp17
gene expression.
Upregulation of Sp17 gene expression in IM-9 by
5-azacytidine
To determine if DNA hypomethylating agents could upregulate the
expression of Sp17 gene, we exposed all eight tumour cell lines to
5-azacytidine (2mM) for 96h. Following culture in control or 5-
azacytidine-containing mediums, total RNA from these cells was
isolated for Northern blot analysis. Autoradiographic signals
corresponding to Sp17 transcripts were only obtained in the four
Sp17-positive tumour cells (ARK-B, ARP-1, KMS-11 and RPMI
8226) when the tumour cells were cultured in medium without any
5-azacytidine (Figure 5). In keeping with the results suggested by
RT-PCR, the Sp17 signal was strongest in KMS-11 and weakest in
ARP-1. No Sp17 signal was observed with H929, IM-9, MM1-R and
U266 cells. However, following culture in 5-azacytidine, Sp17
transcript levels were further increased in ARK-B and ARP-1 cells.
In addition, the 5-azacytidine also induced the expression of Sp17
gene in H929, IM-9 and MM1-R cells that originally did not
express Sp17. When each tumour cell line in 5-azacytidine was
compared to that of its respective control culture, no differences
were observed in the viability or rate of proliferation of the cells.
The increase in the levels of Sp17 transcripts following exposure to
5-azacytidine was therefore due to the upregulation of gene
expression rather than selection of Sp17-positive variants within
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KMS-11 clones
IM-9 clones
Figure 3 Comparison of the levels of methylation at all 46 CpG sites within exon 1 between KMS-11 and IM-9 cells, showing that there was increased
hypomethylation throughout exon 1 in KMS-11 cells that express Sp17 gene.
1234567 8
Substrate
Product
Figure 4 Analysis of 293 cells for CAT activities after plasmid transfection to confirm the role of Sp17 promoter methylation (lane 1¼wild-type 293 cells;
293 cells transfected with pCAT*3 Enhancer-Sp17 promoter; lane 3¼293 cells transfected with the positive control plasmid pCAT*3 Enhancer-SV40
promoter; lane 4¼293 cells transfected with a control plasmid, pcDNA3.1; lane 5¼293 cells transfected with pCAT*3 Enhancer plasmid that did not
contain any promoter; lane 6¼293 cells transfected with pCAT*3 Enhancer-Sp17 promoter/met; lane 7¼product control; lane 8¼substrate control).
12345678
abababababababab
-actin
Sp17
Figure 5 Northern blot analysis to compare the levels of Sp17 transcripts before (a) and after (b) exposure to 5-azacytidine (lane 1¼ARK-B; lane
2¼ARP-1; lane 3¼H929; lane 4¼IM-9; lane 5¼KMS-11; lane 6¼MM1-R; lane 7¼U266; and lane 8¼RPMI 8226).
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expression was related to promoter hypomethylation, bisulphite
conversion was carried out using genomic DNA from IM-9 cells,
before and after preincubation in 5-azacytidine. Significantly more
clones showed hypomethylation at the two HpaII sites amplified by
primer pair IV (at position  350, increased from 0 to 62.5% and
at position  359; increased from 12.5 to 50%; Po0.001) after
exposure to 5-azacytidine, further supporting the possible
involvement of the sequence around these two sites in the control
of Sp17 gene expression. Compared to IM-9 cells that did not
express Sp17 gene when cultured in control medium, the promoter
sequence of IM-9 cells preincubated with 5-azacytidine also
showed more global hypomethylation at the CpG islands (69 vs
27%, Po0.0005).
DISCUSSION
CT antigens are potentially suitable targets for cancer immu-
notherapy because of their limited expression in normal tissues
and their in vivo immunogenicity (Reynolds et al, 1997; Stockert
et al, 1998; Traversari, 1999). Since these targets are often not
essential for the neoplastic process or survival of the tumour cells,
it is not uncommon to observe heterogeneity of expression of these
targets within a tumour lesion. Identification of the mechanisms
regulating the expression of the target genes may therefore lead to
new approaches that upregulate gene expression and circumvent
deficiency within individual patients to improve the outcome of
immunotherapy.
Genetic anomalies occur frequently in MM. These anomalies,
resulted from increased CpG island and decrease global DNA
methylation, lead to the inactivation of many well-characterised
tumour suppressor genes as well as the inactivation of DNA repair
genes. It has been proposed that the expression of genes with CpG-
rich promoters is normally controlled via tissue-specific transcrip-
tion factors (Eden and Cedar, 1994), while for those with CpG-poor
promoters, gene expression is controlled through DNA methyla-
tion (Bird, 1992). However, exceptions can occur. Recent
studies have indicated that DNA methylation, instead of tissue-
specific transcription factors, is the primary regulatory mechan-
isms for the control of expression on a subset of male CpG-rich
germline-specific genes, the MAGE-type genes (De Smet et al,
1999).
Unlike the genes for most other CT antigens, the gene encoding
Sp17 is localised to chromosome 11q rather than X chromosome.
Nevertheless, Sp17 gene expression also exhibits a very restricted
normal tissue expression pattern identical to those by genes
encoding some CT antigens (Lim et al, 2001; De Jong et al, 2002),
suggesting its potential as a target for immunotherapy of MM and
other tumours. Its possible applicability in tumour vaccines has
been supported by in vitro data showing the ability to generate
tumour-specific CTLs from these patients (Chiriva-Internati et al,
2002a,c). However, its applicability may be limited since Sp17 was
only detected in 27% of MM patients. In the light of the strong
therapeutic and diagnostic implications of Sp17 expression, we
have set out to determine the role of DNA methylation in
regulating the presence and levels of expression of Sp17 in MM.
In keeping with our previous results involving the study of fresh
MM tumour cells (Lim et al, 2001), we first showed that not all MM
tumour cell lines express Sp17. The heterogeneity of expression of
Sp17 in MM suggests the lack of functional necessity of Sp17 gene
products in maintaining the malignant phenotypes. Analysis of the
50 region in exon 1 of the gene showed that it is CpG rich,
suggesting the possible promoter function of the sequence. The
promoter function of exon 1 was further confirmed by in vitro
transfection studies showing the ability of exon 1 sequence to allow
the transcription and expression of CAT gene in 293 cells. Using
methylation-sensitive restriction digest/PCR analysis in screening
studies, the CpG region most susceptible to the inactivating action
of methylation was identified by mapping of the different
overlapping gene segments amplified from exon 1. Differences in
the degree of methylation of the CpG sites within the Sp17
promoter sequence were compared and confirmed by bisulphite
conversion and correlated to Sp17 expression in these tumour cell
lines. Analysis of the sequences of the clones indicates some
heterogeneity of DNA methylation within a tumour cell line. The
role of promoter methylation in silencing the Sp17 gene in Sp17-
negative tumour cells was confirmed by demonstrating the
suppression of the CAT gene expression by in vitro methylation
of exon 1. These results therefore provide the first evidence that
the expression of Sp17 gene in MM cell lines is directly dependent
on the methylation status of distinct CpG dinucleotides located in
the promoter regions, a scenario not unlike that in MAGE genes
(De Smet et al, 1999).
In vitro exposure of these MM cells to the DNA hypomethylating
agent, 5-azacytidine, has been recently shown to induce the
expression of different CT antigens (Weiser et al, 2001; Sigalotti
et al, 2002). In the present study, we have found that Sp17 gene
could also be upregulated by exposure of the tumour cells to 5-
azacytidine, except in U266. This finding, nevertheless, further
provides evidence that DNA methylation is involved in the
expression of Sp17 by MM cells. The reason for the failure to
upregulate Sp17 expression in U266 is unclear and remains
speculative. Differences in the metabolism of 5-azacytidine by
different myeloma cell lines may explain this. It should, however,
be noted that the present study does not support the use of 5-
azacytidine to increase the expression of Sp17 in vivo, since the
concentration of the hypomethylating agent used in our experi-
ments was much higher than the tolerable dose in human (Weiser
et al, 2001). Whether or not other hypomethylating agents, when
used at therapeutic doses, will promote the expression of Sp17
remains to be determined.
Various workers have previously demonstrated that changes in
the methylation of the genomes frequently occur in MM (Mays-
Hoopes et al, 1986; Ng et al, 1997). Our results, therefore, suggest
that Sp17 is the expression in myeloma cells as the consequence of
promoter demethylation. Since changes in gene methylation
become more frequent as the disease progresses, it is expected
that the expression of Sp17 in myeloma cells will increase as MM
becomes more advanced.
We previously found that mRNA encoding Sp17 was detected
only in the testis and not any other normal tissues (Lim et al,
2001). Our findings are in keeping with previous investigations of
Sp17 expression using Northern blot analysis in rabbit and baboon
(Richardson et al, 1994; Adoyo et al, 1997). Using RT–PCR, De
Jong et al (2002) were also unable to detect Sp17 mRNA in any
normal tissues except the testis. Weak bands of PCR products
were, however, obtained in several normal tissues, but only after
two rounds of 30-cycle PCR, suggesting that very low level of Sp17
transcripts are present in some normal tissues. However, a recent
study by Frayne and Hall (2002) produced contrasting results.
They demonstrated that Sp17 transcripts could be detected, albeit
at much lower levels than the testis, in many normal tissues after
only one 30-cycle PCR. The apparent discrepancies of results
suggest that it is likely Sp17 is expressed at low levels in some
normal tissues. Other CT antigens such as NY-ESO-1, CT15/fertilin
b and CT-16 are undetectable at 35 cycles of conventional RT–
PCR but have been detected in a limited number of normal tissues
at 40 cycles of real-time quantitative RT–PCR (Scanlan et al,
2002). However, the levels were less than 3% of the level detected
in normal testis and the biological meaning of such low-level
expression is unclear. In the light of the results from the present
study, the apparent conflicting data are not surprising because
random DNA methylation/demethylation errors can occur and are
responsible for leaking expression of the Sp17 genes in some
normal tissues.
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for the regulation of Sp17 gene expression in MM tumour cell
lines. Although DNA methylation is not the primary control
mechanism regulating the expression of most tissue-specific genes,
our results indicate that promoter methylation can serve as the
main regulatory mechanism for the expression of Sp17 in tumour
cell lines. The susceptibility to induction of Sp17 in tumour cells by
hypomethylating agent further supports the role of DNA methyla-
tion in silencing Sp17 gene. Our findings may have therapeutic
implications and provides possible explanation to the leaky
expression of Sp17 in some normal tissues observed in some
studies.
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